BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143:1025-1030. [PMID: 17709661 DOI: 10.1001/archderm.143.8.1025] [Cited by in Crossref: 76] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-8. [PMID: 18226008 DOI: 10.1111/j.1525-139X.2007.00399.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
2 Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol 2018;84:2522-34. [PMID: 30032482 DOI: 10.1111/bcp.13718] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
3 Breathnach SM. Drug Reactions. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-177. [DOI: 10.1002/9781444317633.ch75] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
4 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 48] [Article Influence: 11.1] [Reference Citation Analysis]
5 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
6 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
7 Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61:868-874. [PMID: 19836645 DOI: 10.1016/j.jaad.2009.03.040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
8 van der Molen A. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. Journal of Medical Imaging and Radiation Oncology 2008;52:339-50. [DOI: 10.1111/j.1440-1673.2008.01965.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
9 Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6:553-558. [PMID: 26253982 DOI: 10.1007/s13244-015-0420-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 79] [Article Influence: 18.5] [Reference Citation Analysis]
10 Knobler R, Barr ML, Couriel DR, Ferrara JL, French LE, Jaksch P, Reinisch W, Rook AH, Schwarz T, Greinix H. Extracorporeal photopheresis: Past, present, and future. Journal of the American Academy of Dermatology 2009;61:652-65. [DOI: 10.1016/j.jaad.2009.02.039] [Cited by in Crossref: 84] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
11 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 22] [Article Influence: 6.9] [Reference Citation Analysis]
12 Penfield JG, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium-Based Contrast Agents?: GADOLINIUM CHELATE DIFFERENCES AND NSF RISK. Seminars in Dialysis 2008;21:129-34. [DOI: 10.1111/j.1525-139x.2007.00408.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
13 Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543-2548. [PMID: 18668587 DOI: 10.1002/art.23696] [Cited by in Crossref: 116] [Cited by in F6Publishing: 89] [Article Influence: 8.9] [Reference Citation Analysis]
14 Andreu-Ullrich H. Miscellaneous indications for extracorporeal photochemotherapy (ECP). Transfus Apher Sci 2014;50:363-9. [PMID: 24816437 DOI: 10.1016/j.transci.2014.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
15 Marckmann P. Nephrogenic systemic fibrosis: epidemiology update: . Current Opinion in Nephrology and Hypertension 2008;17:315-9. [DOI: 10.1097/mnh.0b013e3282f4b605] [Cited by in Crossref: 32] [Article Influence: 2.5] [Reference Citation Analysis]
16 Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 2010;55:1040-9. [PMID: 20430497 DOI: 10.1053/j.ajkd.2010.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hazelton JM, Chiu MK, Abujudeh HH. Nephrogenic Systemic Fibrosis: A Review of History, Pathophysiology, and Current Guidelines. Curr Radiol Rep 2019;7. [DOI: 10.1007/s40134-019-0312-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
19 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 247] [Article Influence: 157.0] [Reference Citation Analysis]
20 Goodfellow F, Simchick GA, Mortensen LJ, Stice SL, Zhao Q. Tracking and Quantification of Magnetically Labeled Stem Cells using Magnetic Resonance Imaging. Adv Funct Mater 2016;26:3899-915. [PMID: 28751853 DOI: 10.1002/adfm.201504444] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
21 Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008;34:199-220; ix. [PMID: 18329541 DOI: 10.1016/j.rdc.2007.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
22 Zou Q, Xu H, Liu F, Guo W, Kong X, Wu Y. In the assessment of supratentorial glioma grade: The combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging. Clinical Radiology 2011;66:953-60. [DOI: 10.1016/j.crad.2011.05.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
23 Hachani R, Lowdell M, Birchall M, Thanh NT. Tracking stem cells in tissue-engineered organs using magnetic nanoparticles. Nanoscale 2013;5:11362-73. [PMID: 24108444 DOI: 10.1039/c3nr03861k] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
24 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 176] [Article Influence: 42.0] [Reference Citation Analysis]
25 Galperin TA, Cronin AJ, Leslie KS. Cutaneous manifestations of ESRD. Clin J Am Soc Nephrol. 2014;9:201-218. [PMID: 24115194 DOI: 10.2215/cjn.05900513] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
26 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
27 Kadiyala D, Roer DA, Perazella MA. Nephrogenic Systemic Fibrosis Associated With Gadoversetamide Exposure: Treatment With Sodium Thiosulfate. American Journal of Kidney Diseases 2009;53:133-7. [DOI: 10.1053/j.ajkd.2008.09.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
28 Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 2017;31:1581-94. [PMID: 28786499 DOI: 10.1111/jdv.14466] [Cited by in Crossref: 42] [Cited by in F6Publishing: 11] [Article Influence: 10.5] [Reference Citation Analysis]
29 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
30 Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Appl Immunohistochem Mol Morphol 2010;18:448-52. [PMID: 20485155 DOI: 10.1097/PAI.0b013e3181de372e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
31 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
32 Zhang R, Rose WN. Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis. Case Rep Dermatol Med. 2017;2017:3240287. [PMID: 28695022 DOI: 10.1155/2017/3240287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009;33:819-23. [PMID: 19940643 DOI: 10.1097/RCT.0b013e31819d68ed] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
34 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 74] [Article Influence: 8.5] [Reference Citation Analysis]
35 Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. [PMID: 18952698 DOI: 10.1093/ndt/gfn593] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
36 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
37 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
38 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
39 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
40 Hachani R, Birchall MA, Lowdell MW, Kasparis G, Tung LD, Manshian BB, Soenen SJ, Gsell W, Himmelreich U, Gharagouzloo CA, Sridhar S, Thanh NTK. Assessing cell-nanoparticle interactions by high content imaging of biocompatible iron oxide nanoparticles as potential contrast agents for magnetic resonance imaging. Sci Rep 2017;7:7850. [PMID: 28798327 DOI: 10.1038/s41598-017-08092-w] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
41 Linfert DR, Schell JO, Fine DM. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future: TREATMENT OF NSF. Seminars in Dialysis 2008;21:155-9. [DOI: 10.1111/j.1525-139x.2007.00407.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. European Journal of Radiology 2008;66:187-90. [DOI: 10.1016/j.ejrad.2008.01.032] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
43 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
44 Igreja ACDSM, Mesquita KDC, Cowper SE, Costa IMC. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012;87:597-607. [DOI: 10.1590/s0365-05962012000400013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
45 Panesar M, Yacoub R. What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Seminars in Dialysis 2011;24:373-4. [DOI: 10.1111/j.1525-139x.2011.00913.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
47 Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008;37:457-64. [DOI: 10.1007/s00256-008-0464-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
48 Kuzmina Z, Stroncek D, Pavletic SZ. Extracorporeal photopheresis as a therapy for autoimmune diseases. J Clin Apher 2015;30:224-37. [PMID: 25546289 DOI: 10.1002/jca.21367] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
49 Krishnam MS, Tomasian A, Malik S, Singhal A, Sassani A, Laub G, Finn JP, Ruehm S. Three-Dimensional Imaging of Pulmonary Veins by a Novel Steady-State Free-Precession Magnetic Resonance Angiography Technique Without the Use of Intravenous Contrast Agent: Initial Experience. Investigative Radiology 2009;44:447-53. [DOI: 10.1097/rli.0b013e3181a7c6cb] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
50 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
51 Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. European Journal of Radiology 2008;66:230-4. [DOI: 10.1016/j.ejrad.2008.02.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 160] [Article Influence: 17.2] [Reference Citation Analysis]
52 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
53 Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. [PMID: 20568098 DOI: 10.1002/jca.20240] [Cited by in Crossref: 366] [Cited by in F6Publishing: 284] [Article Influence: 33.3] [Reference Citation Analysis]
54 Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5:157-170. [PMID: 19190625 DOI: 10.1038/ncpneph1040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]